Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
1. A method for making a labeled compound or a salt thereof, wherein the method comprises reacting [5-(5-ethoxymethoxy-benzofuran-2-yl)-6-nitro-pyridin-2-yl]-methyl-carbamic acid tert-butyl ester, or a salt thereof, with a source of 18 F-fluoride to produce 2-(2-[ 18 F]-fluoro-6-methylamino-pyridin-3-yl)-benzofuran-5-ol, or a salt thereof.
2. The method according to claim 1 , wherein, prior to reacting the [5-(5-ethoxymethoxy-benzofuran-2-yl)-6-nitro-pyridin-2-yl]-methyl-carbamic acid tert-butyl ester or salt thereof with a source of 18 F-fluoride, the [5-(5-ethoxymethoxy-benzofuran-2-yl)-6-nitro-pyridin-2-yl]-methyl-carbamic acid tert-butyl ester or salt thereof is provided in crystalline form.
3. The method according to claim 2 , wherein the crystalline form has at least one endothermic event with onset between 70° C. and 300° C.
4. The method according to claim 2 , wherein the crystalline form has an X-ray powder diffraction pattern comprising at least one specific diffraction peak at about 2-theta=6.18°.
5. The method according to claim 2 , wherein the crystalline form has an X-ray powder diffraction pattern comprising at least one specific diffraction peak at about 2-theta=6.18, 9.14, 11.67, 14.98, and 16.44.